دورية أكاديمية
أعرض في EDS

Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion.

التفاصيل البيبلوغرافية
العنوان: Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion.
المؤلفون: Van Acker HH; Laboratory of Experimental Hematology, Tumor Immunology Group (TIGR), Faculty of Medicine and Health Sciences, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium., Anguille S; Division of Hematology, Antwerp University Hospital, Edegem, Belgium.; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium., De Reu H; Laboratory of Experimental Hematology, Tumor Immunology Group (TIGR), Faculty of Medicine and Health Sciences, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium., Berneman ZN; Laboratory of Experimental Hematology, Tumor Immunology Group (TIGR), Faculty of Medicine and Health Sciences, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.; Division of Hematology, Antwerp University Hospital, Edegem, Belgium.; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium., Smits EL; Laboratory of Experimental Hematology, Tumor Immunology Group (TIGR), Faculty of Medicine and Health Sciences, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium.; Center for Oncological Research (CORE), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., Van Tendeloo VF; Laboratory of Experimental Hematology, Tumor Immunology Group (TIGR), Faculty of Medicine and Health Sciences, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.
المصدر: Frontiers in immunology [Front Immunol] 2018 Apr 10; Vol. 9, pp. 658. Date of Electronic Publication: 2018 Apr 10 (Print Publication: 2018).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Print ISSN: 1664-3224 (Print) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: Dendritic Cells/*immunology , Interleukin-15/*immunology , Intraepithelial Lymphocytes/*immunology , Leukemia, Myeloid, Acute/*immunology, Aged ; Aged, 80 and over ; Cancer Vaccines ; Cells, Cultured ; Coculture Techniques ; Female ; Humans ; Male ; Middle Aged
مستخلص: Dendritic cell (DC) vaccination can be an effective post-remission therapy for acute myeloid leukemia (AML). Yet, current DC vaccines do not encompass the ideal stimulatory triggers for innate gamma delta (γδ) T cell anti-tumor activity. Promoting type 1 cytotoxic γδ T cells in patients with AML is, however, most interesting, considering these unconventional T cells are primed for rapid function and exert meaningful control over AML. In this work, we demonstrate that interleukin (IL)-15 DCs have the capacity to enhance the anti-tumoral functions of γδ T cells. IL-15 DCs of healthy donors and of AML patients in remission induce the upregulation of cytotoxicity-associated and co-stimulatory molecules on the γδ T cell surface, but not of co-inhibitory molecules, incite γδ T cell proliferation and stimulate their interferon-γ production in the presence of blood cancer cells and phosphoantigens. Moreover, the innate cytotoxic capacity of γδ T cells is significantly enhanced upon interaction with IL-15 DCs, both towards leukemic cell lines and allogeneic primary AML blasts. Finally, we address soluble IL-15 secreted by IL-15 DCs as the main mechanism behind the IL-15 DC-mediated γδ T cell activation. These results indicate that the application of IL-15-secreting DC subsets could render DC-based anti-cancer vaccines more effective through, among others, the involvement of γδ T cells in the anti-leukemic immune response.
References: Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9692-7. (PMID: 26195801)
PLoS One. 2011;6(6):e20952. (PMID: 21698118)
N Engl J Med. 2015 Sep 17;373(12):1136-52. (PMID: 26376137)
Oncoimmunology. 2015 Apr 1;4(8):e1021538. (PMID: 26405575)
Blood. 2012 Sep 13;120(11):2269-79. (PMID: 22767497)
J Immunother. 2014 Jul-Aug;37(6):321-30. (PMID: 24911793)
Blood. 2011 Dec 22;118(26):6845-8. (PMID: 22067383)
Immunotherapy. 2017 Jan;9(2):111-114. (PMID: 28128710)
Oncotarget. 2015 Dec 29;6(42):44123-33. (PMID: 26675759)
PLoS One. 2015 May 07;10(5):e0123340. (PMID: 25951230)
Blood Cancer J. 2016 Jul 01;6(7):e441. (PMID: 27367478)
Cytokine Growth Factor Rev. 2016 Oct;31:49-59. (PMID: 27325459)
Leukemia. 2016 Aug;30(8):1749-52. (PMID: 26876593)
Oncoimmunology. 2016 Apr 25;5(10 ):e1146843. (PMID: 27853633)
J Immunol. 2016 Jan 15;196(2):645-54. (PMID: 26673141)
Nat Rev Immunol. 2015 Nov;15(11):683-91. (PMID: 26449179)
Pharmacol Ther. 2016 Feb;158:24-40. (PMID: 26617219)
Leukemia. 2016 Feb;30(2):484-91. (PMID: 26239198)
Sci Transl Med. 2016 Dec 7;8(368):368ra171. (PMID: 27928025)
Front Immunol. 2015 Jan 26;6:15. (PMID: 25674089)
Oncotarget. 2017 Feb 21;8(8):13652-13665. (PMID: 28099143)
Blood. 2017 Oct 12;130(15):1713-1721. (PMID: 28830889)
Blood Rev. 2013 Sep;27(5):209-16. (PMID: 23871358)
Front Immunol. 2014 Dec 19;5:648. (PMID: 25566259)
Haematologica. 2017 Jul;102(7):1227-1237. (PMID: 28302711)
Immunol Cell Biol. 2017 Aug;95(7):620-629. (PMID: 28356569)
Cell Immunol. 2015 Jul;296(1):10-21. (PMID: 25659480)
Cancer Res. 2014 Sep 1;74(17):4772-82. (PMID: 24994712)
Front Immunol. 2015 Jan 15;5:679. (PMID: 25642230)
Oncotarget. 2017 May 25;8(34):56968-56979. (PMID: 28915646)
Eur J Immunol. 2011 Feb;41(2):345-55. (PMID: 21268005)
Semin Oncol. 2015 Aug;42(4):562-72. (PMID: 26320061)
Pharmacol Rev. 2015 Oct;67(4):731-53. (PMID: 26240218)
Expert Rev Clin Immunol. 2014 Jan;10(1):19-30. (PMID: 24308838)
J Exp Med. 2000 Mar 6;191(5):771-80. (PMID: 10704459)
J Immunol. 2010 Aug 1;185(3):1770-6. (PMID: 20592281)
Nat Med. 2015 Aug;21(8):938-945. (PMID: 26193342)
Front Immunol. 2014 Dec 11;5:636. (PMID: 25566249)
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1039-1044. (PMID: 29339503)
J Immunol. 2012 Feb 15;188(4):1708-16. (PMID: 22250090)
Blood. 2007 Aug 1;110(3):921-7. (PMID: 17403919)
J Transl Med. 2009 Dec 18;7:109. (PMID: 20021667)
Oncoimmunology. 2016 Sep 2;5(10 ):e1227902. (PMID: 27853652)
Blood. 2011 Jul 28;118(4):992-1001. (PMID: 21633088)
Nat Rev Immunol. 2013 Feb;13(2):88-100. (PMID: 23348415)
Front Immunol. 2017 Jan 09;7:675. (PMID: 28119690)
Hum Vaccin Immunother. 2013 Sep;9(9):1956-61. (PMID: 23778748)
Eur J Immunol. 2004 Aug;34(8):2089-99. (PMID: 15259006)
Curr Drug Targets. 2017;18(3):315-331. (PMID: 25981611)
J Immunol. 2014 Mar 1;192(5):2237-43. (PMID: 24489097)
Cancer Res. 2004 Nov 1;64(21):8062-7. (PMID: 15520217)
Front Immunol. 2013 Dec 31;4:496. (PMID: 24427158)
J Hematol Oncol. 2016 Sep 29;9(1):101. (PMID: 27686372)
Cancer Immunol Res. 2017 Sep;5(9):812-820. (PMID: 28811289)
J Clin Oncol. 2015 Jan 1;33(1):74-82. (PMID: 25403209)
فهرسة مساهمة: Keywords: acute myeloid leukemia; dendritic cell vaccination; immunotherapy; interleukin-15; γδ T cells
المشرفين على المادة: 0 (Cancer Vaccines)
0 (IL15 protein, human)
0 (Interleukin-15)
تواريخ الأحداث: Date Created: 20180426 Date Completed: 20190606 Latest Revision: 20210103
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC5902500
DOI: 10.3389/fimmu.2018.00658
PMID: 29692776
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-3224
DOI:10.3389/fimmu.2018.00658